http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
-
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
-
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress
-
Scholar Rock (SRRK) Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
-
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
-
Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference
-
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
-
Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
-
Scholar Rock Holding Corp. (SRRK) Reports Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months
-
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular At
-
Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference
-
Scholar Rock to Present at Jefferies Global Healthcare Conference 2022
-
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities
-
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress
-
Scholar Rock Holding Corp. (SRRK) Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial
-
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting
-
Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
-
Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress
-
Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference
-
Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
-
Scholar Rock Holding Corp. (SRRK) Provides Corporate Update and Highlights Priorities for 2022
-
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022
-
Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
-
Scholar Rock Holding Corp. (SRRK) Reports Initial Data from DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors
-
Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement int
-
Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress
-
Scholar Rock to Present at Upcoming Healthcare Conferences
-
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology
-
Scholar Rock Holding Corp. (SRRK) Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting
-
Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting
-
Scholar Rock Holding Corp. (SRRK) Announces Issuance of U.S. Patent Protecting SRK-181
-
Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation
-
Scholar Rock Holding Corp. (SRRK) Announces Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial
-
Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress
-
Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference
-
Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer
-
Scholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress
-
Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference
-
Scholar Rock Holding Corp. (SRRK) announces CEO Tony Kingsley has departed
-
Scholar Rock Announces Leadership Change
-
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress
-
Scholar Rock (SRRK) Presents TOPAZ Phase 2 Data Showing Transformative Potential of Apitegromab in Patients with Type 2 and 3 SMA
-
Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical
-
Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting
-
Scholar Rock to Present at Upcoming Healthcare Conferences in June
-
Scholar Rock (SRRK) Receives Fast Track Designation from U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy
-
Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy
-
Scholar Rock Holding Corp. (SRRK) to Present Trials in Progress Poster for SRK-181 DRAGON Phase 1 Clinical Trial at the American Society of Clinical Oncology Annual Meeting
-
Scholar Rock to Present Trials in Progress Poster for SRK-181 DRAGON Phase 1 Clinical Trial at the American Society of Clinical Oncology Annual Meeting

